By OAN Newsroom
American pharmaceutical giant ‘Pfizer‘ has enrolled more than 42,000 people in its phase two trial of its potential COVID-19 vaccine. The company has also said over 35,000 participants have received a second dose of the vaccination.
PFIZER INC – PHASE 2/3 TRIAL OF COVID-19 VACCINE HAS ENROLLED 42,113 PARTICIPANTS & 35,771 PARTICIPANTS HAVE RECEIVED THEIR SECOND VACCINATION
— First Squawk (@FirstSquawk) October 26, 2020
The pharmaceutical company has been one of the front-runners in the race for a coronavirus vaccine. Additionally, President Trump mentioned the company during the final presidential debate.
“Pfizer is doing very well, and we have numerous others,” the President stated. “And then we also have others that we’re working on very closely with other countries, in particular Europe.”
The world is waiting for a safe and effective #COVID19 vaccine. Today our Chairman & CEO penned an open letter to help people understand the criteria we must meet and the expected timelines for our investigational vaccine program. https://t.co/RlhDYq4vK0
— Pfizer Inc. (@pfizer) October 16, 2020
Researchers hope the trial results will be in by November, and if so, they’ll be sent to the FDA for a review process which could take up to four weeks.